Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 13
Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
Authors Mareque M, Montesinos P, Font P, Guinea JM , de la Fuente A, Soto J , Oyagüez I , Brockbank J , Iglesias T, Llinares J, Sierra J
Received 7 July 2021
Accepted for publication 7 July 2021
Published 14 July 2021 Volume 2021:13 Pages 645—646
Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277.
Page 271, Results, Base Case, second line from the bottom, the text “€ 15,134” should read “€ 151,434”.
The authors apologize for this error.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.